OGN — Organon & Co. Stock Price, Chart & AI Report

Negative Jun 22, 2026 • 17:47 UTC GlobeNewswire Inc. • Brodsky & Smith

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Apogee Therapeutics, Inc. (Nasdaq – APGE), Simulations Plus, Inc. (Nasdaq – SLP), Roku, Inc. (Nasdaq – ROKU), TruBridge, Inc. (Nasdaq – TBRG)

Brodsky & Smith law firm has announced investigations into multiple merger transactions, including Apogee Therapeutics (acquired by AbbVie for $135.11/share), Roku (acquired by Fox for $160/share), TruBridge (acquired by Inventurus for $26.25/share), and Organon (acquired by Sun Pharmaceutical for $14/share). The investigations focus on whether the respective boards breached fiduciary duties by failing to conduct fair processes and whether deal consideration provides fair value to shareholders.

APGE ABBV ROKU FOX merger investigation fiduciary duty shareholder litigation deal valuation

Sentiment note

Under investigation for potential board breach of fiduciary duties regarding merger fairness and deal consideration adequacy

Negative Jun 17, 2026 • 01:14 UTC GlobeNewswire Inc. • Halper Sadeh Llc

Halper Sadeh LLC is Investigating Whether LPRO, NUVL, OGN, SUNE are Obtaining Fair Deals for their Shareholders

Investor rights law firm Halper Sadeh LLC is investigating four companies for potential securities law violations and breaches of fiduciary duties related to their proposed acquisitions. The firm is examining whether shareholders are receiving fair consideration and whether insider benefits may be limiting superior competing offers.

LPRO NUVL OGN SUNE shareholder rights merger investigation fiduciary duty securities law

Sentiment note

Under investigation for potential securities law violations and fiduciary duty breaches in its $14.00 per share sale to Sun Pharmaceutical Industries Limited.

Negative Jun 16, 2026 • 19:56 UTC GlobeNewswire Inc. • Brodsky & Smith

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Simulations Plus, Inc. (Nasdaq – SLP), Roku, Inc. (Nasdaq – ROKU), TruBridge, Inc. (Nasdaq – TBRG), Organon & Co. (NYSE – OGN)

Brodsky & Smith law firm is investigating four merger transactions to determine whether company boards breached fiduciary duties by failing to conduct fair processes and provide fair value to shareholders. The investigations involve Simulations Plus ($18.50/share), Roku ($160.00/share), TruBridge ($26.25/share), and Organon ($14.00/share).

SLP ROKU TBRG OGN merger investigation fiduciary duty shareholder litigation fair value

Sentiment note

Under investigation for potential board breach of fiduciary duties regarding fair process and fair value in $11.75 billion all-cash acquisition by Sun Pharmaceutical for $14.00/share

Negative Jun 10, 2026 • 00:04 UTC GlobeNewswire Inc. • Halper Sadeh Llc

Halper Sadeh LLC is Investigating Whether NUVL, SUNE, OGN, TMHC are Obtaining Fair Deals for their Shareholders

Investor rights law firm Halper Sadeh LLC is investigating four major corporate transactions for potential securities law violations and breaches of fiduciary duties. The investigations cover Nuvalent's $124/share sale to GSK, SUNation Energy's merger with Suniva, Organon's $14/share sale to Sun Pharmaceutical, and Taylor Morrison's $72.50/share sale to Berkshire Hathaway. The firm is seeking increased consideration and additional disclosures on behalf of shareholders.

NUVL SUNE OGN TMHC M&A investigation shareholder rights fiduciary duty securities law

Sentiment note

Under investigation for potential securities violations in Sun Pharmaceutical sale; suggests deal terms may not be fair to shareholders

Positive May 22, 2026 • 06:20 UTC GlobeNewswire Inc. • Na

Hanmi Pharmaceutical se asocia con Organon para exportar terapias combinadas al Sudeste Asiático

Hanmi Pharmaceutical has signed a supply agreement with Organon to export three combination medicines in cardiovascular and respiratory therapeutic areas to Malaysia and the Philippines. Organon will handle marketing, distribution, and sales in these markets, with potential for expansion in the medium to long term.

OGN combination therapies supply agreement Southeast Asia Malaysia Philippines cardiovascular respiratory

Sentiment note

The partnership allows Organon to expand its product portfolio in fast-growing Southeast Asian markets without manufacturing burden, leveraging Hanmi's combination therapy expertise. This strengthens its market position and addresses growing demand for chronic disease treatments.

Positive May 22, 2026 • 06:20 UTC GlobeNewswire Inc. • Na

Hanmi Pharmaceutical Faz Parceria com a Organon para Exportação de Terapias de Combinação para o Sudeste Asiático

Hanmi Pharmaceutical has signed a supply agreement with Organon to export three combination medicines for cardiovascular and respiratory therapeutic areas to Malaysia and the Philippines. Organon will handle marketing, distribution, and sales in these markets, with potential for medium to long-term expansion. The partnership leverages the growing demand for combination therapies in Southeast Asia's rapidly expanding pharmaceutical market.

OGN combination therapies Southeast Asia expansion Malaysia Philippines cardiovascular respiratory pharmaceutical partnership

Sentiment note

The partnership allows Organon to expand its product portfolio in fast-growing Southeast Asian markets without manufacturing burden, aligning with its commitment to increase access to medicines in emerging markets and strengthen its presence across 140+ markets.

Negative May 14, 2026 • 17:51 UTC GlobeNewswire Inc. • Brodsky & Smith

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Veris Residential, Inc. (NYSE – VRE), XOMA Royalty Corporation (Nasdaq – XOMA), Organon & Co. (NYSE – OGN), RE/MAX Holdings, Inc. (NYSE – RMAX)

Brodsky & Smith law firm announced investigations into four merger transactions, examining whether company boards breached fiduciary duties by failing to conduct fair processes and pay fair value to shareholders. The investigations involve Veris Residential ($19.00/share), XOMA Royalty ($39.00/share), Organon ($14.00/share), and RE/MAX Holdings ($13.80/share or stock election).

VRE XOMA XOMAO XOMAP merger investigation fiduciary duty shareholder litigation fair value

Sentiment note

Under investigation for potential breach of fiduciary duties regarding fair process and fair value in $14.00/share acquisition

Negative May 7, 2026 • 01:14 UTC GlobeNewswire Inc. • Halper Sadeh Llc

Halper Sadeh LLC is Investigating Whether HLX, OGN, XOMA, RMAX are Obtaining Fair Deals for their Shareholders

Halper Sadeh LLC, an investor rights law firm, is investigating four companies for potential securities law violations and breaches of fiduciary duties related to proposed mergers and acquisitions. The firm is examining whether shareholders are receiving fair consideration and whether insider benefits may be prioritized over ordinary shareholder interests.

HLX OGN XOMA XOMAO merger investigation shareholder rights fiduciary duty securities law

Sentiment note

Under investigation regarding sale to Sun Pharmaceutical for $14.00 per share; potential concerns about whether price represents fair value for shareholders

Negative May 5, 2026 • 18:53 UTC GlobeNewswire Inc. • Halper Sadeh Llc

Halper Sadeh LLC is Investigating Whether MKC, LEG, OGN, KW are Obtaining Fair Deals for their Shareholders

Investor rights law firm Halper Sadeh LLC is investigating four major companies for potential securities law violations and breaches of fiduciary duties. The investigations concern McCormick & Company's merger with Unilever's Foods business, Leggett & Platt's sale to Somnigroup International, Organon & Co.'s sale to Sun Pharmaceutical, and Kennedy-Wilson Holdings' sale to a consortium led by its CEO. The firm is seeking increased consideration and additional disclosures on behalf of shareholders.

MKC MKC.V LEG OGN shareholder investigation merger acquisition fiduciary duty

Sentiment note

Under investigation for potential unfair deal terms in $14.00 per share sale to Sun Pharmaceutical; firm questioning whether price represents fair value

Positive May 1, 2026 • 18:35 UTC Benzinga • Caroline Ryan

Deal Dispatch: Sirius XM Mulls Purchase Of iHeartMedia, Uber Buys FlyTaxi, Wren Kitchens Bankruptcy

Sirius XM is in preliminary discussions to acquire iHeartMedia in a potential merger of America's largest satellite radio provider and radio station owner. Other major deals include Eli Lilly acquiring AI startup Profluent for up to $2.25 billion, Sun Pharmaceutical acquiring Organon for $11.75 billion, and Uber purchasing Hong Kong-based FlyTaxi. Meanwhile, several companies filed for bankruptcy including Wren Kitchens, FreshRealm, and Smokey Bones BBQ.

SIRI IHRT LLY UBER M&A acquisitions bankruptcy Sirius XM

Sentiment note

Being acquired by Sun Pharmaceutical for $14 per share in cash, providing shareholders with a defined exit at agreed valuation.

Negative Apr 28, 2026 • 01:23 UTC GlobeNewswire Inc. • Halper Sadeh Llc

Halper Sadeh LLC is Investigating Whether OGN, XOMA, RMAX, SLNO are Obtaining Fair Deals for their Shareholders

Investor rights law firm Halper Sadeh LLC is investigating four pharmaceutical and real estate companies for potential securities law violations and breaches of fiduciary duties related to their proposed acquisitions. The firm is examining whether shareholders are receiving fair consideration and whether insider benefits may be limiting superior competing offers.

OGN XOMA XOMAO XOMAP M&A investigation shareholder rights fiduciary duty securities law

Sentiment note

Under investigation for potential securities law violations and fiduciary duty breaches related to $14.00 per share sale to Sun Pharmaceutical, suggesting shareholders may not be receiving fair consideration

Positive Apr 27, 2026 • 21:34 UTC The Motley Fool • Josh Kohn-Lindquist

Stock Market Today, April 27: Organon Shares Surge After Sun Pharma Agrees to Acquire Company in All Cash Deal

Organon & Co. shares surged 16.87% to $13.16 after Sun Pharmaceutical Industries agreed to acquire the women's health company in an all-cash deal valued at $14 per share. The acquisition, expected to close in early 2027, comes as relief for Organon, which has struggled since its 2021 spinoff from Merck with $8 billion in long-term debt and declining profitability.

OGN PFE BMY CELGR acquisition all-cash deal pharmaceutical women's health

Sentiment note

Stock surged 16.87% on acquisition announcement at $14 per share in cash. Company benefits from debt relief as it carries $8 billion in long-term debt versus $3 billion market cap, addressing profitability concerns.